Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling.
Animals
Cell Line
Cell Line, Tumor
Cell Proliferation
/ physiology
DNA-Binding Proteins
/ metabolism
F-Box-WD Repeat-Containing Protein 7
/ metabolism
Female
HEK293 Cells
Humans
Interferon-gamma
/ metabolism
Mice
Mice, Inbred BALB C
Neoplasm Metastasis
/ pathology
Receptors, Interferon
/ metabolism
Signal Transduction
/ physiology
Transcription Factors
/ metabolism
Triple Negative Breast Neoplasms
/ metabolism
Tumor Microenvironment
/ physiology
Interferon gamma Receptor
Journal
Nature cell biology
ISSN: 1476-4679
Titre abrégé: Nat Cell Biol
Pays: England
ID NLM: 100890575
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
04
03
2019
accepted:
28
02
2020
pubmed:
15
4
2020
medline:
8
7
2020
entrez:
15
4
2020
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC) is characterized by a high degree of immune infiltrate in the tumour microenvironment, which may influence the fate of TNBC cells. We reveal that loss of the tumour suppressive transcription factor Elf5 in TNBC cells activates intrinsic interferon-γ (IFN-γ) signalling, promoting tumour progression and metastasis. Mechanistically, we find that loss of the Elf5-regulated ubiquitin ligase FBXW7 ensures stabilization of its putative protein substrate IFN-γ receptor 1 (IFNGR1) at the protein level in TNBC. Elf5
Identifiants
pubmed: 32284542
doi: 10.1038/s41556-020-0495-y
pii: 10.1038/s41556-020-0495-y
pmc: PMC8237104
mid: NIHMS1697050
doi:
Substances chimiques
DNA-Binding Proteins
0
ELF5 protein, human
0
F-Box-WD Repeat-Containing Protein 7
0
FBXW7 protein, human
0
Receptors, Interferon
0
Transcription Factors
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
591-602Subventions
Organisme : NCI NIH HHS
ID : K22 CA193661
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA193711
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA237243
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Kwa, M. J. & Adams, S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here. Cancer 124, 2086–2103 (2018).
pubmed: 29424936
doi: 10.1002/cncr.31272
Liu, Z., Li, M., Jiang, Z. & Wang, X. A comprehensive immunologic portrait of triple-negative breast cancer. Transl. Oncol. 11, 311–329 (2018).
pubmed: 29413765
pmcid: 5884188
doi: 10.1016/j.tranon.2018.01.011
Garcia-Teijido, P., Cabal, M. L., Fernandez, I. P. & Perez, Y. F. Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting. Clin. Med. Insights Oncol. 10, 31–39 (2016).
pubmed: 27081325
pmcid: 4822722
Kumar, S. et al. DeltaNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. J. Clin. Invest. 128, 5095–5109 (2018).
pubmed: 30295647
pmcid: 6205409
doi: 10.1172/JCI99673
Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
pubmed: 24202395
pmcid: 3954707
doi: 10.1038/nm.3394
Markowitz, J., Wesolowski, R., Papenfuss, T., Brooks, T. R. & Carson, W. E. 3rd Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res. Treat. 140, 13–21 (2013).
pubmed: 23828498
pmcid: 3773691
doi: 10.1007/s10549-013-2618-7
Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322 (2012).
pubmed: 22439926
doi: 10.1016/j.ccr.2012.02.022
Zhou, J. et al. Cancer-associated fibroblasts correlate with tumor-associated macrophages infiltration and lymphatic metastasis in triple negative breast cancer patients. J. Cancer 9, 4635–4641 (2018).
pubmed: 30588247
pmcid: 6299377
doi: 10.7150/jca.28583
Yu, T. & Di, G. Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chin. J. Cancer Res. 29, 237–252 (2017).
pubmed: 28729775
pmcid: 5497211
doi: 10.21147/j.issn.1000-9604.2017.03.10
Deng, L. et al. Immune profiles of tumor microenvironment and clinical prognosis among women with triple-negative breast cancer. Cancer Epidemiol. Biomark. Prev. 28, 1977–1985 (2019).
doi: 10.1158/1055-9965.EPI-19-0469
Yuan, Z. Y., Luo, R. Z., Peng, R. J., Wang, S. S. & Xue, C. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. Onco. Targets Ther. 7, 1475–1480 (2014).
pubmed: 25187727
pmcid: 4149399
doi: 10.2147/OTT.S61838
Choi, Y. S., Chakrabarti, R., Escamilla-Hernandez, R. & Sinha, S. Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev. Biol. 329, 227–241 (2009).
pubmed: 19269284
doi: 10.1016/j.ydbio.2009.02.032
Harris, J. et al. Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol. Endocrinol. 20, 1177–1187 (2006).
pubmed: 16469767
doi: 10.1210/me.2005-0473
Zhou, J. et al. Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. EMBO J. 24, 635–644 (2005).
pubmed: 15650748
pmcid: 548648
doi: 10.1038/sj.emboj.7600538
Chakrabarti, R. et al. Elf5 regulates mammary gland stem/progenitor cell fate by influencing notch signaling. Stem Cells 30, 1496–1508 (2012).
pubmed: 22523003
pmcid: 5606133
doi: 10.1002/stem.1112
Chakrabarti, R. et al. Elf5 inhibits the epithelial–mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat. Cell Biol. 14, 1212–1222 (2012).
pubmed: 23086238
pmcid: 3500637
doi: 10.1038/ncb2607
Mojic, M. & Takeda, K. & Hayakawa, Y.The dark side of IFN-γ: its role in promoting cancer immunoevasion. Int. J. Mol. Sci. 19, E89 (2017).
pubmed: 29283429
doi: 10.3390/ijms19010089
Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
doi: 10.1126/science.1203486
Mimura, K. et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 109, 43–53 (2018).
pubmed: 29034543
doi: 10.1111/cas.13424
Zaidi, M. R. et al. Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature 469, 548–553 (2011).
pubmed: 21248750
pmcid: 3140101
doi: 10.1038/nature09666
Yang, J. & Weinberg, R. A. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818–829 (2008).
pubmed: 18539112
doi: 10.1016/j.devcel.2008.05.009
Thiery, J. P. Epithelial–mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442–454 (2002).
pubmed: 12189386
doi: 10.1038/nrc822
Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265–273 (2009).
pubmed: 19262571
doi: 10.1038/nrc2620
Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial–mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
pubmed: 19945376
doi: 10.1016/j.cell.2009.11.007
Lin, N. U. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118, 5463–5472 (2012).
pubmed: 22544643
doi: 10.1002/cncr.27581
De Ruijter, T. C., Veeck, J., de Hoon, J. P., van Engeland, M. & Tjan-Heijnen, V. C. Characteristics of triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 137, 183–192 (2011).
pubmed: 21069385
doi: 10.1007/s00432-010-0957-x
Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434 (2007).
pubmed: 17671126
doi: 10.1158/1078-0432.CCR-06-3045
Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418–8423 (2003).
pubmed: 12829800
pmcid: 166244
doi: 10.1073/pnas.0932692100
Echeverria, G. V. et al. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat. Commun. 9, 5079 (2018).
pubmed: 30498242
pmcid: 6265294
doi: 10.1038/s41467-018-07406-4
Aprelikova, O. et al. Development and preclinical application of an immunocompetent transplant model of basal breast cancer with lung, liver and brain metastases. PLoS ONE 11, e0155262 (2016).
pubmed: 27171183
pmcid: 4865188
doi: 10.1371/journal.pone.0155262
Katayama, H. et al. An autoimmune response signature associated with the development of triple-negative breast cancer reflects disease pathogenesis. Cancer Res. 75, 3246–3254 (2015).
pubmed: 26088128
pmcid: 4676710
doi: 10.1158/0008-5472.CAN-15-0248
Jezequel, P. et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 17, 43 (2015).
pubmed: 25887482
pmcid: 4389408
doi: 10.1186/s13058-015-0550-y
Choi, Y. S., Cheng, J., Segre, J. & Sinha, S. Generation and analysis of Elf5-LacZ mouse: unique and dynamic expression of Elf5 (ESE-2) in the inner root sheath of cycling hair follicles. Histochem. Cell Biol. 129, 85–94 (2008).
pubmed: 17938949
doi: 10.1007/s00418-007-0347-x
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).
pubmed: 28650338
pmcid: 5531419
doi: 10.1172/JCI91190
Liu, X. et al. Activation of the JAK/STAT-1 signaling pathway by IFN-γ can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG. J. Immunol. 181, 449–463 (2008).
pubmed: 18566411
doi: 10.4049/jimmunol.181.1.449
Villarino, A. V., Kanno, Y., Ferdinand, J. R. & O'Shea, J. J. Mechanisms of Jak/STAT signaling in immunity and disease. J. Immunol. 194, 21–27 (2015).
pubmed: 25527793
doi: 10.4049/jimmunol.1401867
Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84–88 (2006).
pubmed: 16397499
doi: 10.1038/nature04372
Yeh, C. H., Bellon, M. & Nicot, C. FBXW7: a critical tumor suppressor of human cancers. Mol. Cancer 17, 115 (2018).
pubmed: 30086763
pmcid: 6081812
doi: 10.1186/s12943-018-0857-2
Gossage, L., Eisen, T. & Maher, E. R. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer 15, 55–64 (2015).
pubmed: 25533676
doi: 10.1038/nrc3844
Shin, H. Y. et al. Hierarchy within the mammary STAT5-driven Wap super-enhancer. Nat. Genet. 48, 904–911 (2016).
pubmed: 27376239
pmcid: 4963296
doi: 10.1038/ng.3606
Marchetti, M. et al. Stat-mediated signaling induced by type I and type II interferons (IFNs) is differentially controlled through lipid microdomain association and clathrin-dependent endocytosis of IFN receptors. Mol. Biol. Cell 17, 2896–2909 (2006).
pubmed: 16624862
pmcid: 1483027
doi: 10.1091/mbc.e06-01-0076
Takeuchi, Y. & Nishikawa, H. Roles of regulatory T cells in cancer immunity. Int. Immunol. 28, 401–409 (2016).
pubmed: 27160722
pmcid: 4986235
doi: 10.1093/intimm/dxw025
Vinay, D. S. et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35, S185–S198 (2015).
pubmed: 25818339
doi: 10.1016/j.semcancer.2015.03.004
Facciabene, A., Motz, G. T. & Coukos, G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72, 2162–2171 (2012).
pubmed: 22549946
pmcid: 3342842
doi: 10.1158/0008-5472.CAN-11-3687
Zhou, Q., Facciponte, J., Jin, M., Shen, Q. & Lin, Q. Humanized NOD-SCID IL2rg
pubmed: 24513265
doi: 10.1016/j.canlet.2013.10.015
Andre, M. C. et al. Long-term human CD34
pubmed: 20668220
doi: 10.4049/jimmunol.1000583
DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514–1520 (2011).
pubmed: 22019887
pmcid: 3553601
doi: 10.1038/nm.2454
Gradishar, W. J. et al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J. Natl Compr. Cancer Netw. 15, 433–451 (2017).
doi: 10.6004/jnccn.2017.0044
Blows, F. M. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7, e1000279 (2010).
pubmed: 20520800
pmcid: 2876119
doi: 10.1371/journal.pmed.1000279
Lu, W. & Kang, Y. Epithelial–mesenchymal plasticity in cancer progression and metastasis. Dev. Cell 49, 361–374 (2019).
pubmed: 31063755
pmcid: 6506183
doi: 10.1016/j.devcel.2019.04.010
Soundararajan, R. et al. Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy. Cancers (Basel) 11, E714 (2019).
doi: 10.3390/cancers11050714
McNutt, M. Cancer immunotherapy. Science 342, 1417 (2013).
pubmed: 24357273
doi: 10.1126/science.1249481
Vikas, P., Borcherding, N. & Zhang, W. The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag. Res. 10, 6823–6833 (2018).
pubmed: 30573992
pmcid: 6292225
doi: 10.2147/CMAR.S185176
Dirix, L. Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res. Treat. 167, 671–686 (2018).
pubmed: 29063313
doi: 10.1007/s10549-017-4537-5
Nanda, R. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460–2467 (2016).
pubmed: 27138582
pmcid: 6816000
doi: 10.1200/JCO.2015.64.8931
Li, C. H., Karantza, V., Aktan, G. & Lala, M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res. 21, 143 (2019).
pubmed: 31842957
pmcid: 6916124
doi: 10.1186/s13058-019-1210-4
Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725–731 (2010).
pubmed: 20020197
doi: 10.1007/s10549-009-0674-9
Busino, L. et al. Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat. Cell Biol. 14, 375–385 (2012).
pubmed: 22388891
pmcid: 3339029
doi: 10.1038/ncb2463
Bayne, L. J. & Vonderheide, R. H. Multicolor flow cytometric analysis of immune cell subsets in tumor-bearing mice. Cold Spring Harb. Protoc. 2013, 955–960 (2013).
pubmed: 24086051
Pearton, D. J., Broadhurst, R., Donnison, M. & Pfeffer, P. L. Elf5 regulation in the trophectoderm. Dev. Biol. 360, 343–350 (2011).
pubmed: 22020251
doi: 10.1016/j.ydbio.2011.10.007
Deome, K. B., Faulkin, L. J. Jr, Bern, H. A. & Blair, P. B. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res. 19, 515–520 (1959).
pubmed: 13663040
Chakrabarti, R. & Kang, Y. Transplantable mouse tumor models of breast cancer metastasis. Methods Mol. Biol. 1267, 367–380 (2015).
pubmed: 25636479
doi: 10.1007/978-1-4939-2297-0_18
Welte, T. et al. Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat. Cell Biol. 18, 632–644 (2016).
pubmed: 27183469
pmcid: 4884142
doi: 10.1038/ncb3355
Chakrabarti, R. et al. ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat. Cell Biol. 16, 1004–1015 (2014).
pubmed: 25241036
pmcid: 4183725
doi: 10.1038/ncb3040